Investors: Capture New, Unaddressed Market Opportunities

60° Pharmaceuticals (60P): A two-pronged mission for investors

  • Commitment to developing and commercialization of new therapies for the treatment and prevention of infectious/tropical diseases with high unmet medical need
  • Commitment to selection of products and projects with high potential economic value and return on investment

Building on established products with innovative R&D

The Company’s lead product, ARAKODA® (tafenoquine), is already FDA-approved, with a proven safety record in clinical trials, and competitive advantages over other products in for malaria prevention.


60P intends to evaluate the malaria prophylactic dose for safety and efficacy in:

  • Treatment of COVID-19 disease
  • Treatment and prevention of fungal diseases
  • Treatment and prevention of tick-borne diseases such as babesiosis


60P has an exclusive license from the U.S. Army for ARAKODA for all non-P. vivax malaria indications and a supportive intellectual property estate. Repositioning ARAKODA for these indications entails less risk, and continues 60P’s tradition of efficient use of private capital to secure advanced clinical development milestones.

Promising Pipeline of Antiviral Products

  • Celgosivir for Dengue, RSV, and COVID-19

    • Broad spectrum host-targeted, Priority Review Voucher (PRV)-eligible antiviral with good Phase II clinical safety profile
    • Fills treatment void: Currently no effective therapeutic products against dengue

The experience to succeed

Founded by industry veterans, 60P has a leadership team with over 80 years of combined pharmaceutical business experience–including new product development, product management, regulatory approval, and marketing, with a track record of achieving advanced development milestones with efficient use of private capital.

Innovation and product development

To innovate new tropical disease treatments, 60P collaborates with other public and private entities to proceed collectively.

A partnership built on trust and efficiency

As 60P continues to achieve significant clinical development milestones, the expansion arising out of investment will enable 60P to accelerate its path to market. Ideally, 60P seeks to augment its experience in development, manufacturing, and commercialization of drugs.


Headquarters: Washington, DC (USA)

Research and Development: Australia


  • 2010: 60P established
  • 2012: Secured $2 million in initial funding
  • 2013: Established an Australian subsidiary to support global research projects
  • 2014: Commercialization of tafenoquine for malaria prophylaxis initiated with US Army
  • 2016: Knight Pharmaceuticals provided $4 million in financing to support the 60P tafenoquine program
  • 2017: 60P filed IND for tafenoquine with a target indication for the prevention of malaria
  • 2019: 60P launches first product in the United States, Arakoda (tafenoquine) tablets
  • 2021: 60P concludes Phase II study of ARAKODA in COVID-19 patients
FORWARD LOOKING STATEMENTS: This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our expectations surrounding the potential of our product candidates, ARAKODA, and expectations regarding our pipeline, including trial design and development timelines. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: uncertainty around and costs associated with the development of ARAKODA as a potential treatment for COVID-19 and our other product candidates; dependence on management, directors and other key personnel; the impact of the COVID-19 pandemic on our business; our need for substantial additional funding; our dependence on the success of our most advanced product candidates; risks related to the regulatory approval process; risks associated with the clinical development process and reliance on interim or topline clinical trial results; risks related to healthcare laws and other legal compliance matters; risks related to potential commercialization; risks related to manufacturing and our dependence on third parties; risks relating to intellectual property; our ability to maintain effective internal control over financial reporting and the significant costs as a result of operating as a company. These important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

Cases and 1 Million deaths in the U.S. from COVID-19 infections


Annual deaths from malaria globally


Travelers to endemic regions per annum


Dengue infections per year


1025 Connecticut Ave. NW, Suite 1000, Washington, DC 20036